Articles from Mammogen, Inc.

MammoLink joins Mammogen’s KATELYN-ERIN trial, expanding community access to a prospective study evaluating blood-based RNA biology for breast cancer detection

Executive Director of the Inova Saville Cancer Screening and Prevention Center will lead KATELYN-ERIN, Mammogen’s large prospective study evaluating its blood-based RNA assay to support breast cancer detection

NEWPORT BEACH, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Mammogen, a female-led predictive health company developing RNA-powered molecular diagnostics for women’s health, today appointed Elise Berman, M.D., as Chief Medical Officer. Dr. Berman brings more than two decades of leadership across breast imaging, medical affairs, and clinical development. She joins Mammogen as the company advances genTRU-breast™ through clinical validation and toward commercialization.

Institutional financing supports pivotal prospective clinical advancement and commercialization of Mammogen’s RNA-powered molecular diagnostics platform

Brilliantly and Mammogen, Inc., two female-led women’s health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physician’s office.